Topic: venture capital (VC)
Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company advances four RNA-targeting drugs.
Talaris Therapeutics raised $100 million to move its cell therapy for kidney transplant patients into phase 3.
Nocion is working on positively charged molecules that silence nociceptors—the neurons that send pain or itch signals—without affecting other neurons.
The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease.
The first close of the targeted $200 million fund tees Hatteras up to make a fresh batch of seed and early-stage biotech investments.
Ajax Health's raise will be used to help identify potentially disruptive startups toward the ultimate goal of achieving an exit within four years.
With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.
The funding will advance Inozyme's lead program into clinical trials for rare mineralization disorders in babies and children.
A new Atlas-incubated startup focused on rare forms of muscle diseases has got off a $50 million series A with experienced executives at the helm.
AgomAb Therapeutics is coming out of stealth with €21 million to develop agonistic monoclonal antibodies that could potentially treat a range of diseases.